메뉴 건너뛰기




Volumn 71, Issue 4, 2016, Pages 463-472

Niacin is still beneficial. Implications from an updated meta-regression analysis

Author keywords

HDL C; Meta analysis; Niacin; Nicotinic acid; Non HDL C; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

EID: 84982282670     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.2143/AC.71.4.3159701     Document Type: Article
Times cited : (6)

References (40)
  • 1
    • 0016630250 scopus 로고
    • Clofibrate and niacin in coronary heart disease
    • Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
    • (1975) JAMA , vol.231 , pp. 360-381
  • 5
    • 77952397461 scopus 로고    scopus 로고
    • Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    • Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210: 353-61.
    • (2010) Atherosclerosis , vol.210 , pp. 353-361
    • Bruckert, E.1    Labreuche, J.2    Amarenco, P.3
  • 9
    • 84872679028 scopus 로고    scopus 로고
    • The current state of niacin in cardiovascular disease prevention: A systematic review and meta-regression
    • Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013; 61: 440-6.
    • (2013) J am Coll Cardiol , vol.61 , pp. 440-446
    • Lavigne, P.M.1    Karas, R.H.2
  • 10
    • 84868201763 scopus 로고    scopus 로고
    • Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials
    • Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 2012; 110: 1468-76.
    • (2012) Am J Cardiol , vol.110 , pp. 1468-1476
    • Robinson, J.G.1    Wang, S.2    Jacobson, T.A.3
  • 12
    • 0028034227 scopus 로고
    • Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
    • Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994: 344: 1182-6.
    • (1994) Lancet , vol.344 , pp. 1182-1186
    • Sacks, F.M.1    Pasternak, R.C.2    Gibson, C.M.3    Rosner, B.4    Stone, P.H.5
  • 13
    • 41949131921 scopus 로고    scopus 로고
    • Tershakovec. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia
    • Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51: 1564-72.
    • (2008) J am Coll Cardiol , vol.51 , pp. 1564-1572
    • Guyton, J.R.1    Brown, B.G.2    Fazio, S.3    Polis, A.4    Tomassini, J.E.5
  • 14
    • 0023910325 scopus 로고
    • Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid
    • Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
    • (1988) Acta Med Scand , vol.223 , pp. 405-418
    • Carlson, L.A.1    Rosenhamer, G.2
  • 15
    • 0025685469 scopus 로고
    • Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
    • Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-12.
    • (1990) JAMA , vol.264 , pp. 3007-3012
    • Kane, J.P.1    Malloy, M.J.2    Ports, T.A.3    Phillips, N.R.4    Diehl, J.C.5    Havel, R.J.6
  • 16
    • 84948007950 scopus 로고
    • Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
    • Blankenhorn DH, Nessim SA, Johnson RL. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
    • (1987) JAMA , vol.257 , pp. 3233-3240
    • Blankenhorn, D.H.1    Nessim, S.A.2    Johnson, R.L.3
  • 17
    • 10044281651 scopus 로고    scopus 로고
    • Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    • Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
    • (2004) Circulation , vol.110 , pp. 3512-3517
    • Taylor, A.J.1    Sullenberger, L.E.2    Lee, H.J.3    Lee, J.K.4    Grace, K.A.5
  • 19
    • 19944426989 scopus 로고    scopus 로고
    • A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events
    • Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005; 142: 95-104.
    • (2005) Ann Intern Med , vol.142 , pp. 95-104
    • Whitney, E.J.1    Krasuski, R.A.2    Personius, B.E.3    Michalek, J.E.4    Maranian, A.M.5    Kolasa, M.W.6    Monick, E.7    Brown, B.G.8    Gotto, A.M.9
  • 20
    • 33751217682 scopus 로고    scopus 로고
    • The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3
    • Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22: 2243-50.
    • (2006) Curr Med Res Opin , vol.22 , pp. 2243-2250
    • Taylor, A.J.1    Lee, H.J.2    Sullenberger, L.E.3
  • 22
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials
    • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Baigent, C.1    Blackwell, L.2    Emberson, J.3    Holland, L.E.4    Reith, C.5    Bhala, N.6    Peto, R.7    Barnes, E.H.8    Keech, A.9    Simes, J.10    Collins, R.11
  • 23
    • 84904490497 scopus 로고    scopus 로고
    • Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomised controlled trials including 117,411 patients
    • Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014; 349: g4379.
    • (2014) BMJ , pp. 349
    • Keene, D.1    Price, C.2    Shun-Shin, M.J.3    Francis, D.P.4
  • 25
    • 77951483195 scopus 로고    scopus 로고
    • Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids
    • Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 2010; 30: 968-75.
    • (2010) Arterioscler Thromb Vasc Biol , vol.30 , pp. 968-975
    • Wu, B.J.1    Yan, L.2    Charlton, F.3    Witting, P.4    Barter, P.J.5    Rye, K.A.6
  • 29
    • 84885844867 scopus 로고    scopus 로고
    • The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality
    • Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 2013; 62: 1909-10.
    • (2013) J am Coll Cardiol , vol.62 , pp. 1909-1910
    • Khera, A.V.1    Patel, P.J.2    Reilly, M.P.3    Rader, D.J.4
  • 31
    • 84906259943 scopus 로고    scopus 로고
    • Triglycerides and cardiovascular disease
    • Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626-35.
    • (2014) Lancet , vol.384 , pp. 626-635
    • Nordestgaard, B.G.1    Varbo, A.2
  • 33
    • 84898899088 scopus 로고    scopus 로고
    • Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease
    • Zambon A, Zhao XQ, Brown BG, Brunzell JD. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 2014; 113: 1494-8.
    • (2014) Am J Cardiol , vol.113 , pp. 1494-1498
    • Zambon, A.1    Zhao, X.Q.2    Brown, B.G.3    Brunzell, J.D.4
  • 34
    • 84919663233 scopus 로고    scopus 로고
    • Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia
    • Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol 2015; 115: 178-82.
    • (2015) Am J Cardiol , vol.115 , pp. 178-182
    • Khera, A.V.1    Qamar, A.2    Reilly, M.P.3    Dunbar, R.L.4    Rader, D.J.5
  • 36
    • 84911380386 scopus 로고    scopus 로고
    • Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis
    • Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis 2014; 237: 829-37.
    • (2014) Atherosclerosis , vol.237 , pp. 829-837
    • Ambegaonkar, B.M.1    Tipping, D.2    Polis, A.B.3    Tomassini, J.E.4    Tershakovec, A.M.5
  • 37
    • 79960539641 scopus 로고    scopus 로고
    • ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
    • European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
    • (2011) Eur Heart J , vol.32 , pp. 1769-1818
    • Reiner, Z.1    Catapano, A.L.2    De Backer, G.3    Graham, I.4    Taskinen, M.R.5    Wiklund, O.6    Agewall, S.7    Alegria, E.8    Chapman, M.J.9    Durrington, P.10    Erdine, S.11    Halcox, J.12    Hobbs, R.13    Kjekshus, J.14    Filardi, P.P.15    Riccardi, G.16    Storey, R.F.17    Wood, D.18
  • 38
    • 84925351969 scopus 로고    scopus 로고
    • Lipid lowering with PCSK9 inhibitors
    • Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014; 10: 563-75.
    • (2014) Nat Rev Cardiol , vol.10 , pp. 563-575
    • Dadu, R.T.1    Ballantyne, C.M.2
  • 40
    • 84864861863 scopus 로고    scopus 로고
    • Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial
    • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-71.
    • (2012) Lancet , vol.380 , pp. 565-571
    • Ridker, P.M.1    Pradhan, A.2    Macfadyen, J.G.3    Libby, P.4    Glynn, R.J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.